0001209191-23-005452.txt : 20230130
0001209191-23-005452.hdr.sgml : 20230130
20230130160025
ACCESSION NUMBER: 0001209191-23-005452
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230126
FILED AS OF DATE: 20230130
DATE AS OF CHANGE: 20230130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Iyengar Vijay K
CENTRAL INDEX KEY: 0001670000
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12400
FILM NUMBER: 23567633
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INCYTE CORP
CENTRAL INDEX KEY: 0000879169
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 943136539
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
BUSINESS PHONE: 3024986700
MAIL ADDRESS:
STREET 1: 1801 AUGUSTINE CUT-OFF
CITY: WILMINGTON
STATE: DE
ZIP: 19803
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE CORP
DATE OF NAME CHANGE: 20030318
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE GENOMICS INC
DATE OF NAME CHANGE: 20000710
FORMER COMPANY:
FORMER CONFORMED NAME: INCYTE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930902
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-26
0
0000879169
INCYTE CORP
INCY
0001670000
Iyengar Vijay K
1801 AUGUSTINE CUT-OFF
WILMINGTON
DE
19803
0
1
0
0
EVP, GMAPPS
Common Stock
2023-01-26
4
M
0
7000
68.62
A
49835
D
Common Stock
2023-01-26
4
S
0
7000
85.00
D
42835
D
Non-Qualified Stock Option (right to buy)
68.62
2023-01-26
4
M
0
7000
0.00
D
2028-07-01
Common Stock
7000
0
D
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person.
Includes an aggregate of 40,178 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting on July 2, 2019 and the remainder vesting monthly over three years.
/s/ Elizabeth Feeney, Attorney-In-Fact
2023-01-30